Sara López-Tamargo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sara López-Tamargo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Xose S. Puente
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain
23 shared publications - Alberto M. Pendas
Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain
21 shared publications - Anne Laure Todeschini
Université Paris Cité, CNRS, Institut Jacques Monod Paris France
21 shared publications - Aurora Astudillo
Hospital Universitario Central de Asturias
21 shared publications - Elena Llano
Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain
21 shared publications - Manuel Sánchez-Martín
Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
21 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
table s4 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open Accesstable s4 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
table s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open Accesstable s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
U1 snRNA mutation reshapes tumor microenvironment in chronic lymphocytic leukemia: a role for CD44-mediated signaling
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal mature B lymphocytes in peripheral blood, bone marrow, lymphoid tissues, and extranodal sites. Genes involved in RNA splicing such as SF3B1 and U1 are frequently mutated in CLL, leading to altered splicing and generation of tumor neoepitopes. To study the impact of these mutations on the tumor microenvironment (TME), we have developed a comprehensive single-cell atlas of unmutated CLL encompassing 26 bone marrow and lymph node tumor samples from 23 U-CLL patients with mutations in U1 (n=7), SF3B1 (n=8), or without mutations in splicing genes (n=10). We observed high intra-tumor heterogeneity, discerning 12 transcriptional programs, one linked to the U1 g.A3>C mutation and characterized by NFKB hyperactivation. T cell and NK compartments exhibited site- and mutation-specific enrichment, with increased CD4 + regulatory cells (Treg) and CD8 + exhausted cells in lymph nodes, while U1 -mutant tumors showed increased CD8 + cytotoxic activity, with a predominance of effector-like CD8 + cells. Single-cell T cell receptor sequencing revealed clonotype expansion in U1 -mutated tumors, particularly in CD8 + effector and exhausted cells, suggesting a neoantigen-driven immune response. Cell-to-cell interaction analysis identified CD44 as a key mediator in U1 -mutated tumors, showing pro-B survival interactions as those involving MIF-CD44-CD74. Furthermore, interactions between CD80 on CLL cells and CTLA4 on Tregs and CD8 + exhausted were upregulated, reflecting an immunosuppressive phenotype associated with U1 mutated CLL. These findings highlight the complex interplay between mutations in CLL and the TME, offering novel avenues for alternative therapeutic strategies for U-CLL with mutations in U1 .
Open AccessU1 snRNA mutation reshapes tumor microenvironment in chronic lymphocytic leukemia: a role for CD44-mediated signaling
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal mature B lymphocytes in peripheral blood, bone marrow, lymphoid tissues, and extranodal sites. Genes involved in RNA splicing such as SF3B1 and U1 are frequently mutated in CLL, leading to altered splicing and generation of tumor neoepitopes. To study the impact of these mutations on the tumor microenvironment (TME), we have developed a comprehensive single-cell atlas of unmutated CLL encompassing 26 bone marrow and lymph node tumor samples from 23 U-CLL patients with mutations in U1 (n=7), SF3B1 (n=8), or without mutations in splicing genes (n=10). We observed high intra-tumor heterogeneity, discerning 12 transcriptional programs, one linked to the U1 g.A3>C mutation and characterized by NFKB hyperactivation. T cell and NK compartments exhibited site- and mutation-specific enrichment, with increased CD4 + regulatory cells (Treg) and CD8 + exhausted cells in lymph nodes, while U1 -mutant tumors showed increased CD8 + cytotoxic activity, with a predominance of effector-like CD8 + cells. Single-cell T cell receptor sequencing revealed clonotype expansion in U1 -mutated tumors, particularly in CD8 + effector and exhausted cells, suggesting a neoantigen-driven immune response. Cell-to-cell interaction analysis identified CD44 as a key mediator in U1 -mutated tumors, showing pro-B survival interactions as those involving MIF-CD44-CD74. Furthermore, interactions between CD80 on CLL cells and CTLA4 on Tregs and CD8 + exhausted were upregulated, reflecting an immunosuppressive phenotype associated with U1 mutated CLL. These findings highlight the complex interplay between mutations in CLL and the TME, offering novel avenues for alternative therapeutic strategies for U-CLL with mutations in U1 .
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
table s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open Accesstable s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
table s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open Accesstable s1 from The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors